ischemic stroke
Conditions
Interventions
Treatment in the intervention group will consist of intravenous acylated
ghrelin, 600micrg dissolved in 50cc normal saline, by bolus (short term)
infusion in 30 minutes, twice daily, for five days.
Sponsors
Rijnstate Ziekenhuis
Eligibility
Age
18 Years to 64 Years
Inclusion criteria
Inclusion criteria: - a clinical diagnosis of acute ischemic stroke, caused by intracranial large vessel occlusion of the anterior circulation (distal intracranial carotid artery or middle (M1/proximal M2) cerebral artery) confirmed by neuro-imaging (CTA or MRA), - treatment with EVT, defined as groin puncture in the angio suite, - CT or MRI ruling out intracranial hemorrhage, - a pre-EVT score of at least 10 on the NIHSS, - age of 18 years or older, - written informed consent.
Exclusion criteria
Exclusion criteria: - pre-stroke disability defined as mRS >=2, - life expectancy shorter than one year, - child bearing potential.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| The primary objective of this study is to assess the effect of ghrelin on the severity of the neurological deficit at seven days after symptom onset in patients with acute ischemic stroke caused by large vessel occlusion of the anterior circulation and treated with EVT. | — |
Secondary
| Measure | Time frame |
|---|---|
| Secondary objectives are assessment of effects of ghrelin on • functional outcome at 90 days (expressed as the score on the modified Rankin Scale (mRS)), • neurological deficit at one and three days after symptom onset (expressed as scores on the NIHSS), • infarct size at day 3±1 (based on MRI measurements), • blood glucose levels at days 1-7, • mean blood pressure at days 1-7, • temperature at days 1-7, • safety (number of SAEs; mortality). | — |
Countries
Netherlands
Outcome results
None listed